GRC 27864
Acute Pain
Phase 2Active
Key Facts
About glenmark
Glenmark Pharmaceuticals has evolved from its 1977 origins as an Indian generics manufacturer into a global, publicly traded biopharmaceutical enterprise with a strategic U.S. headquarters. The company operates on a hybrid model, combining the stable revenue base of a generics business with targeted R&D investments in novel Respiratory, Dermatology, and Oncology therapies. This strategy is supported by significant global infrastructure, including 11 manufacturing facilities and 6 R&D centers, aiming to deliver both innovative treatments and broad accessibility to patients in over 80 countries.
View full company profileTherapeutic Areas
Other Acute Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| OLINVYK (oliceridine) | Trevena | Approved |
| Cebranopadol | Tris Pharma | Phase 3 |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical or Phase 1 |
| VX-548 | Vertex Pharmaceuticals | Phase 3 |
| Maxigesic® Oral | AFT Pharmaceuticals | Approved |